BIOPHARMA INVESTMENT FIRM SYRIDEX BIO ADDRESSES HEALTH EQUITY BY FUNDING R&D OF THERAPIES DISPROPORTIONATELY AFFECTING UNDERSERVED POPULATIONS.
Princeton-based Syridex Bio is a biopharma investment firm that makes early-stage, venture creation investments in innovative treatments that can bring transformative changes to diseases disproportionately affecting underserved communities. It is uniquely focused on double bottom-line returns, delivering compelling returns for investors while accelerating health equity.
Syridex Bio was founded on the belief that everyone deserves a fair and just opportunity to attain their highest level of health. For too long, deep inequities have persisted across our pharmaceutical, biotechnology, and medical systems. Despite increased public attention on the problem in recent years, progress remains far too slow.
Syridex Bio is addressing this gap in the market by strategically investing in therapies that treat diseases disproportionately affecting underserved communities. By financing the development of drugs and treatments addressing the world’s greatest health disparities, it is convinced that it can accelerate health equity globally and achieve strong financial returns for its investors.
Sicklerville, NJ native Squire Servance established Syridex Bio in 2022. As Founder and Managing Partner, Servance oversees the impact-driven investment firm’s operations, growth strategy, investment decisions, and fundraising execution. Servance attended Rutgers University where he double majored in biomedical engineering and cell biology & neuroscience as part of his lifelong dream to help others through his interest in medicine. After earning his JD and MBA from Duke University, he held leadership roles at life sciences companies Repligen and Baxter, where he gained valuable experience and insights on what it takes to bring medicine from R&D and clinical trials to FDA approval and onto the market. While ensuring that investors experience strong returns for their investment is always top of mind, improving the future for patients of color around the world is also very much a labor of love–so much so that Servance named Syridex Bio for his two daughters by combining the first syllables of each of their names.
Innovation for innovation’s sake isn’t a great strategy, but when you have an important mission like helping to solve health equity disparities, it’s extremely motivational,” says Servance. “I view Syridex Bio as an innovation-enabler because tons of medical researchers would welcome the opportunity to discover new therapies to treat diseases like sickle cell and lupus–they just need the funding to enable them to do so. I also believe that Syridex Bio will demonstrate that investing in therapies to help underserved populations is not only right ethically, but a smart financial decision that will pay off big dividends for our investors in the long term.”
Looking ahead, Syridex Bio’s anticipates that next year it will begin making investments in its first round of identified innovative therapies. In addition to investing in new therapies to treat patients of color, Syridex Bio will also begin looking at additional ways to address the significant health gaps that currently exist.
